Exactech Announces New Tissue Distribution Initiatives

Apr 30, 2001, 01:00 ET from Exactech, Inc.

    GAINESVILLE, Fla., April 18 /PRNewswire/ -- Exactech, Inc. (Nasdaq:   EXAC)
 announced today that Tissue Banks International (TBI) will be the exclusive
 distributor of Opteform(TM) bone graft material in California. In addition,
 Exactech's existing representatives in California will aid in distribution of
 TBI's full range of TranZgraft(R) tissue offerings and will continue to
 distribute Opteform as part of the arrangement. Regeneration Technologies.
 Inc. of Alachua, Florida and Exactech are the producers of Opteform.
     Under the new agreement, thirteen TBI representatives will immediately
 begin distributing Opteform in California.  Exactech said it expects
 additional TBI representatives will be distributing Opteform in California by
 the end of the year.
     Exactech's initial entrance into the distribution of allograft tissue
 began with Opteform bone graft material in 1998.  Revenues from distribution
 of Opteform in 2000 were $5.3 million.
     Exactech President Tim Seese said, "This begins the process of expanding
 our distribution capability and enables us to offer a full line of tissue
 allografts and services to meet the needs of surgeons, patients and the
 hospital community. This agreement coincides with the hiring of eight new
 tissue specialists to work with our independent agents outside of California
 to further boost our tissue service efforts. Training sessions for these new
 tissue specialists have already been completed."
     Exactech CEO Bill Petty said, "Exactech's strategy is to provide
 biological and mechanical technologies that offer the best solutions for bone
 and joint restoration. A combination of internal development and external
 alliances are key to achieving this goal. We consider our work with TBI an
 important step that will ensure the prompt placement of these allograft
 tissues where they are most needed."
     TBI's President and CEO Jerry Cole said, "This new undertaking with
 Exactech assists us in achieving the most comprehensive distribution service
 for allografts that improve the quality of life for thousands of Americans
 each year. Moreover, it helps us provide tissues most needed by patients in
 the communities most active in donating tissues to TBI."
     Headquartered in Baltimore, MD, TBI is a non-profit network of eye and
 tissue banks. Many of its transplant banks recover such tissues as bone,
 ligaments and tendons that restore mobility, as well as skin used in burn and
 reconstructive surgery, heart valves to correct cardiac conditions and
 saphenous veins to remedy circulatory problems. The TBI network numbers 33 US
 locations including a tissue processing and distribution center in San Rafael,
 CA.
     Based in Gainesville, Fla., Exactech develops and markets orthopaedic
 implant devices, related surgical instruments and biologic products to
 hospitals and physicians. The company manufactures many of its orthopaedic
 devices at its Gainesville facility. Exactech's orthopaedic products are used
 in the restoration of bones and joints that have deteriorated as a result of
 injury or diseases such as arthritis. Exactech markets its products in the
 United States and in 17 countries in Europe, Asia, Australia and Latin
 America. Regeneration Technologies, Inc. and Exactech are the producers of
 Opteform.
     Copies of EXAC press releases, SEC filings, current price quotes and other
 valuable information for investors may be found on the websites
 http://www.exac.com and http://www.hawkassociates.com
     This release contains various forward looking statements within the
 meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
 Securities Exchange Act of 1934 which represent the company's expectations or
 beliefs concerning future events of the company's financial performance. These
 forward-looking statements are further qualified by important factors that
 could cause actual results to differ materially from those in the forward
 looking statements.  These factors include the effect of competitive pricing,
 the company's dependence on the ability of third party manufacturers to
 produce components on a basis which is cost-effective to the company, market
 acceptance of the company's products and the effects of government regulation.
 Results actually achieved may differ materially from expected results included
 in these statements.
 
 

SOURCE Exactech, Inc.
    GAINESVILLE, Fla., April 18 /PRNewswire/ -- Exactech, Inc. (Nasdaq:   EXAC)
 announced today that Tissue Banks International (TBI) will be the exclusive
 distributor of Opteform(TM) bone graft material in California. In addition,
 Exactech's existing representatives in California will aid in distribution of
 TBI's full range of TranZgraft(R) tissue offerings and will continue to
 distribute Opteform as part of the arrangement. Regeneration Technologies.
 Inc. of Alachua, Florida and Exactech are the producers of Opteform.
     Under the new agreement, thirteen TBI representatives will immediately
 begin distributing Opteform in California.  Exactech said it expects
 additional TBI representatives will be distributing Opteform in California by
 the end of the year.
     Exactech's initial entrance into the distribution of allograft tissue
 began with Opteform bone graft material in 1998.  Revenues from distribution
 of Opteform in 2000 were $5.3 million.
     Exactech President Tim Seese said, "This begins the process of expanding
 our distribution capability and enables us to offer a full line of tissue
 allografts and services to meet the needs of surgeons, patients and the
 hospital community. This agreement coincides with the hiring of eight new
 tissue specialists to work with our independent agents outside of California
 to further boost our tissue service efforts. Training sessions for these new
 tissue specialists have already been completed."
     Exactech CEO Bill Petty said, "Exactech's strategy is to provide
 biological and mechanical technologies that offer the best solutions for bone
 and joint restoration. A combination of internal development and external
 alliances are key to achieving this goal. We consider our work with TBI an
 important step that will ensure the prompt placement of these allograft
 tissues where they are most needed."
     TBI's President and CEO Jerry Cole said, "This new undertaking with
 Exactech assists us in achieving the most comprehensive distribution service
 for allografts that improve the quality of life for thousands of Americans
 each year. Moreover, it helps us provide tissues most needed by patients in
 the communities most active in donating tissues to TBI."
     Headquartered in Baltimore, MD, TBI is a non-profit network of eye and
 tissue banks. Many of its transplant banks recover such tissues as bone,
 ligaments and tendons that restore mobility, as well as skin used in burn and
 reconstructive surgery, heart valves to correct cardiac conditions and
 saphenous veins to remedy circulatory problems. The TBI network numbers 33 US
 locations including a tissue processing and distribution center in San Rafael,
 CA.
     Based in Gainesville, Fla., Exactech develops and markets orthopaedic
 implant devices, related surgical instruments and biologic products to
 hospitals and physicians. The company manufactures many of its orthopaedic
 devices at its Gainesville facility. Exactech's orthopaedic products are used
 in the restoration of bones and joints that have deteriorated as a result of
 injury or diseases such as arthritis. Exactech markets its products in the
 United States and in 17 countries in Europe, Asia, Australia and Latin
 America. Regeneration Technologies, Inc. and Exactech are the producers of
 Opteform.
     Copies of EXAC press releases, SEC filings, current price quotes and other
 valuable information for investors may be found on the websites
 http://www.exac.com and http://www.hawkassociates.com
     This release contains various forward looking statements within the
 meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
 Securities Exchange Act of 1934 which represent the company's expectations or
 beliefs concerning future events of the company's financial performance. These
 forward-looking statements are further qualified by important factors that
 could cause actual results to differ materially from those in the forward
 looking statements.  These factors include the effect of competitive pricing,
 the company's dependence on the ability of third party manufacturers to
 produce components on a basis which is cost-effective to the company, market
 acceptance of the company's products and the effects of government regulation.
 Results actually achieved may differ materially from expected results included
 in these statements.
 
 SOURCE  Exactech, Inc.